{"id":"renin-angiotensin-system-blockers","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough (ACE inhibitors)"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Fatigue"},{"rate":"0.1-0.5","effect":"Angioedema"},{"rate":"5-15","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL432162","moleculeType":"Small molecule","molecularWeight":"411.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs work by either blocking the enzyme ACE (angiotensin-converting enzyme) that produces angiotensin II, or by directly antagonizing the angiotensin II type 1 receptor (AT1). By reducing angiotensin II signaling, they cause vasodilation, decrease aldosterone secretion, and reduce sodium and water retention, leading to lower blood pressure and improved cardiac function.","oneSentence":"Renin-angiotensin system blockers inhibit the formation or action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and decreasing cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:41.930Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT07262723","phase":"PHASE2, PHASE3","title":"Levosimendan in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Chittagong Medical College","startDate":"2025-12-01","conditions":"Acute Decompensated Heart Failure (ADHF)","enrollment":332},{"nctId":"NCT02596126","phase":"PHASE3","title":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-07","conditions":"Myocardial Infarction, Cardiovascular Disease","enrollment":2499},{"nctId":"NCT06093971","phase":"NA","title":"Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2023-11-17","conditions":"Prostate Tumor","enrollment":112},{"nctId":"NCT05972785","phase":"","title":"Long-term Use of CCB and Breast Cancer Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curtin University","startDate":"2022-07-01","conditions":"Hypertension,Essential, Breast Cancer","enrollment":68500},{"nctId":"NCT05169411","phase":"","title":"Preserving Kidney Function in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-09-22","conditions":"Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease","enrollment":20240},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06382571","phase":"","title":"Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2016-01-01","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":396},{"nctId":"NCT02245230","phase":"PHASE1","title":"Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2015-01","conditions":"Hypertension, Hypertension, Essential","enrollment":24},{"nctId":"NCT05726916","phase":"PHASE3","title":"Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-09","conditions":"Hypertensive Emergency-associated Hemolytic Uremic Syndrome","enrollment":66},{"nctId":"NCT05865665","phase":"","title":"Registry Of Best Up-titration STrategies in Acute Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Heart Initiative","startDate":"2023-06","conditions":"Acute Heart Failure","enrollment":5000},{"nctId":"NCT05418361","phase":"","title":"The Effect of RAAS Blockers on ACE2 Levels","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-06-15","conditions":"Renin-Angiotensin System","enrollment":100},{"nctId":"NCT05243446","phase":"","title":"Cardiorenal Effecs of Losartan in Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Medical University of Gdansk","startDate":"2015-09","conditions":"Renal Transplant Failure, Cardiovascular Complication","enrollment":740},{"nctId":"NCT02929329","phase":"PHASE3","title":"Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2017-01-06","conditions":"Heart Failure","enrollment":8256},{"nctId":"NCT01091961","phase":"NA","title":"Study of Preoperative Management of Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Medications","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT03066804","phase":"PHASE3","title":"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-22","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":2572},{"nctId":"NCT05007054","phase":"","title":"Long-Term Outcomes in Patients With Three-Vessel Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2021-05-01","conditions":"Three Vessel Coronary Disease","enrollment":4300},{"nctId":"NCT04286399","phase":"PHASE4","title":"Asian Diabetes Outcomes Prevention Trial","status":"RECRUITING","sponsor":"National Heart Centre Singapore","startDate":"2019-07-01","conditions":"Diabetes Mellitus, Cardiovascular Diseases","enrollment":2400},{"nctId":"NCT01669928","phase":"PHASE4","title":"Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-04","conditions":"Hypertension","enrollment":103},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT04374110","phase":"","title":"Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2020-05-05","conditions":"COVID, Hypertension, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT04374695","phase":"","title":"Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19","status":"UNKNOWN","sponsor":"Versailles Hospital","startDate":"2020-05-01","conditions":"COVID-19","enrollment":700},{"nctId":"NCT00283686","phase":"PHASE3","title":"HALT Progression of Polycystic Kidney Disease Study A","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-01","conditions":"Kidney, Polycystic","enrollment":558},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":"Heart Failure (HF)","enrollment":80},{"nctId":"NCT03195023","phase":"PHASE4","title":"Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)","status":"UNKNOWN","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2015-06","conditions":"Renal Insufficiency, Chronic, Proteinuria","enrollment":106},{"nctId":"NCT03621111","phase":"NA","title":"A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction","status":"UNKNOWN","sponsor":"Azienda ULSS 5 Polesana","startDate":"2018-02-19","conditions":"Myocardial Infarction, Acute, ST Segment Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction (nSTEMI)","enrollment":120},{"nctId":"NCT03526042","phase":"NA","title":"Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2017-09-10","conditions":"Atherosclerosis, Lupus Nephritis","enrollment":40},{"nctId":"NCT01237028","phase":"NA","title":"Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-03","conditions":"IgA Nephropathy","enrollment":168},{"nctId":"NCT01500590","phase":"PHASE4","title":"Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2011-11","conditions":"Diabetes, Hypertensive Disease","enrollment":1400},{"nctId":"NCT01454583","phase":"","title":"Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany","status":"COMPLETED","sponsor":"Stiftung Institut fuer Herzinfarktforschung","startDate":"2008-10","conditions":"Arterial Hypertension","enrollment":15337},{"nctId":"NCT01557140","phase":"PHASE4","title":"A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2003-05","conditions":"Chagas Cardiomyopathy, Heart Failure, Dilated Cardiomyopathy","enrollment":42},{"nctId":"NCT01893788","phase":"PHASE4","title":"Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy","status":"UNKNOWN","sponsor":"Nagoya University","startDate":"2013-04","conditions":"Hypertensive Left Ventricular Hypertrophy","enrollment":100},{"nctId":"NCT01173029","phase":"","title":"Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events","status":"COMPLETED","sponsor":"Universidade Gama Filho","startDate":"2001-06","conditions":"Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction","enrollment":92},{"nctId":"NCT01198275","phase":"PHASE3","title":"n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2006-01","conditions":"Atrial Fibrillation","enrollment":199},{"nctId":"NCT00224549","phase":"PHASE4","title":"PHARES Study: Management of Resistant Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-04","conditions":"Hypertension","enrollment":180},{"nctId":"NCT00310778","phase":"PHASE1","title":"Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-03","conditions":"Healthy","enrollment":64},{"nctId":"NCT00572312","phase":"NA","title":"Optimalization of Nephroprotection Using Atorvastatin (Sortis)","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2005-02","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":466,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ramipril","irbesartan"],"phase":"marketed","status":"active","brandName":"Renin-angiotensin system blockers","genericName":"Renin-angiotensin system blockers","companyName":"Hospital Authority, Hong Kong","companyId":"hospital-authority-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Renin-angiotensin system blockers inhibit the formation or action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and decreasing cardiac workload. Used for Hypertension, Heart failure, Post-myocardial infarction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}